王芬;平凡;童安莉;赵维纲;连小兰;李伟;
WANG Fen;PING Fan;TONG An-li;ZHAO Wei-gang;LIAN Xiao-lan;LI Wei;Department of Endocrinology,Key Laboratory of Endocrinology of Ministry of Health,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院内分泌科卫生部内分泌重点实验室

摘要(Abstract)：

目的探讨累及甲状腺的朗格汉斯组织细胞增生症(Langerhans'cell histocytosis,LCH)的临床特点。方法回顾性分析2004年1月至2014年12月北京协和医院明确诊断有甲状腺受累的6例LCH患者的临床资料并总结其临床表现、诊断、治疗和预后情况。结果 6例患者中男性4例,女性2例,起病年龄9²4岁,平均年龄(16.1±5.7)岁;6例患者均有垂体后叶受累,4例有肺脏受累,3例有肝脏受累;4例患者甲状腺自身抗体阴性,2例阳性;4例患者通过甲状腺粗针穿刺活检获得病理证实;5例患者采用化疗方案治疗;随访4例患者中3例病情稳定无进展。结论在有多器官受累的甲状腺肿大患者中,需进一步排除LCH甲状腺受累的可能性,必要时进行甲状腺穿刺,特别是粗针穿刺以明确病理诊断,同时在LCH甲状腺受累患者中要特别注意有无肝脏受累。
Objective To investigate the clinical characteristics of Langerhans' cell histocytosis( LCH)involving the thyroid gland. Methods We reviewed 6 cases of histologically confirmed LCH with thyroid gland involvement in Peking Union Medical College Hospital in the period of January 2004 to December 2014 and analyzed their clinical menifestations,diagnosis,treatment,and prognosis. Results There were 4 males and 2 females in the 6 patients,whose ages of onset were 9- 24 years with a mean age of( 16. 1 ± 5. 7) years. All the 6cases had posterior pituitary involvement,4 cases had lung involvement,and 3 cases had liver involvement.There were 4 cases with negative thyroid autoantibodies and 2 cases with positive thyroid autoantibodies. Four cases were pathologically confirmed by core-needle aspiration biopsy. Five cases were treated with chemotherapy. In the 4 cases followed up,3 were in progress-free stable status. Conclusions LCH with thyroid involvement should be considered in thyromegaly patients with multiple organs involvement. Thyroid aspiration,especially core-needle aspiration biopsy,is required to confirm pathological diagnosis if necessary. Special attention should be paid to detect liver involvement in patients with thyroid LCH.

关键词(KeyWords)： 朗格汉斯组织细胞增生症;甲状腺疾病
Langerhans' cell histocytosis;thyroid disease

Abstract:

Keywords:

基金项目(Foundation): 国家临床重点专科建设项目(WBYZ2011-873)

作者(Authors): 王芬;平凡;童安莉;赵维纲;连小兰;李伟;
WANG Fen;PING Fan;TONG An-li;ZHAO Wei-gang;LIAN Xiao-lan;LI Wei;Department of Endocrinology,Key Laboratory of Endocrinology of Ministry of Health,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

参考文献(References)：

• [1]Willman CL,Busque L,Griffith BB,et al.Langerhans'-cell histiocytosis(histiocytosis X)——a clonal proliferative disease[J].N Engl J Med,1994,331:154-160.
• [2]Yu RC,Chu C,Buluwela L,et al.Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis[J].Lancet,1994,343:767-768.
• [3]Donadieu J,Rolon MA,Thomas C,et al.Endocrine involvement in pediatric-onset Langerhans'cell histiocytosis:a population-based study[J].J Pediatr,2004,144:344-350.
• [4]Nezelof C,Basset F,Rousseau MF.Histiocytosis X histogenetic arguments for a Langerhans cell origin[J].Biomedicine,1973,18:365-371.
• [5]Merad M,Manz MG,Karsunky H,et al.Langerhans cells renew in the skin throughout life under steady-state conditions[J].Nat Immunol,2002,3:1135-1141.
• [6]Brown NA,Furtado LV,Betz BL,et al.High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis[J].Blood,2014,124:1655-1658.
• [7]Haroche J,Cohen-Aubart F,Emile JF,et al.Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation[J].Blood,2013,121:1495-1500.
• [8]Howarth DM,Gilchrist GS,Mullan BP,et al.Langerhans cell histiocytosis:diagnosis,natural history,management,and outcome[J].Cancer,1999,85:2278-2290.
• [9]Lieberman PH,Jones CR,Steinman RM,et al.Langerhans cell(eosinophilic)granulomatosis.A clinicopathologic study encompassing 50 years[J].Am J Surg Pathol,1996,20:519-552.
• [10]Thompson LD,Wenig BM,Adair CF,et al.Langerhans cell histiocytosis of the thyroid:a series of seven cases and a review of the literature[J].Mod Pathol,1996,9:145-149.
• [11]Xia CX,Li R,Wang ZH,et al.A rare cause of goiter:Langerhans cell histiocytosis of the thyroid[J].Endocr J,2012,59:47-54.
• [12]Patten DK,Wani Z,Tolley N.Solitary langerhans histiocytosis of the thyroid gland:a case report and literature review[J].Head Neck Pathol,2012,6:279-289.
• [13]Chen ED,Cheng P,Cai YF,et al.Ultrasonographic features of Langerhans cell histiocytosis of the thyroid[J].Int J Clin Exp Pathol,2014,7:1229-1235.
• [14]Ceyran AB,Senol S,Bayraktar B,et al.Langerhans cell histiocytosis of the thyroid with multiple cervical lymph node involvement accompanying metastatic thyroid papillary carcinoma[J].Case Rep Pathol,2014,2014:184237.
• [15]Egeler RM,Neglia JP,Puccetti DM,et al.Association of Langerhans cell histiocytosis with malignant neoplasms[J].Cancer,1993,71:865-873.
• [16]Lassalle S,Hofman V,Santini J,et al.Isolated Langerhans cell histiocytosis of the thyroid and Graves'disease:an unreported association[J].Pathology,2008,40:525-527.
• [17]Sangtian J,Riangwiwat T,Triamchaisri S,et al.Fine-needle aspiration biopsy of langerhans cell histiocytosis of thyroid gland[J].J Clin Endocrinol Metab,2015,100:15-16.
• [18]Behrens RJ,Levi AW,Westra WH,et al.Langerhans cellhistiocytosis of the thyroid:a report of two cases and review of the literature[J].Thyroid,2001,11:697-705.
• [19]Grois N,Potschger U,Prosch H,et al.Risk factors for diabetes insipidus in langerhans cell histiocytosis[J].Pediatr Blood Cancer,2006,46:228-233.
• [20]Gadner H,Grois N,Arico M,et al.A randomized trial of treatment for multisystem Langerhans'cell histiocytosis[J].J Pediatr,2001,138:728-734.
• [21]Gandolfi L,Adamo S,Pileri A,et al.Multisystemic and multiresistant Langerhans cell histiocytosis:a case treated with BRAF inhibitor[J].J Natl Compr Canc Netw,2015,13:715-718.